Search the Newsreel

PTC takes a chance on Sangamo’s Fabry disease gene therapy

PTC Therapeutics has acquired an experimental gene therapy for Fabry disease, ST-920, from the bankrupt Sangamo Therapeutics for up to $211 million. Analysts view this as a risky but potentially high-reward move, as the treatment is nearing FDA approval and could offer a superior …

PTC Therapeutics’ $211M Bid Wins Bankruptcy Auction for Sangamo Gene Therapy

PTC Therapeutics has won a bankruptcy auction for Sangamo Therapeutics' gene therapy candidate, isaralgagene civaparvovec (ST-920), for Fabry disease, with a bid of $111 million upfront and up to $100 million in milestone payments. This acquisition expands PTC's rare disease pipeline, bringing a therapy …

PTC Therapeutics to Acquire ST-920 Fabry Gene Therapy

PTC Therapeutics (PTCT) is acquiring ST-920, a BLA-stage Fabry gene therapy, from Sangamo Therapeutics for $111 million upfront and up to $100 million in milestones. This acquisition aims to expand PTC's rare disease portfolio and facilitate accelerated FDA approval by late 2026, with a …

Bankrupt Sangamo scores at least $163 million in asset sale, which had two big winners

Bankrupt Sangamo Therapeutics secured at least $163 million from an asset sale, with Eli Lilly and PTC Therapeutics emerging as the primary buyers. This auction marks a crucial step in winding down Sangamo's 31-year history, a company that spent $1.7 billion on drug technologies …

How Ptc Therapeutics Inc. (PTCT) Affects Rotational Strategy Timing

This article analyzes Ptc Therapeutics Inc. (PTCT) using AI models to provide institutional trading strategies. It highlights a positive near-term sentiment within a long-term strength context, despite a mid-term weak bias, and details specific position, momentum breakout, and risk hedging strategies with entry zones, …

Why PTC Therapeutics (PTCT) Is Up 6.7% After Profit Beat, Higher Guidance And New Board Appointment

PTC Therapeutics (PTCT) saw its stock rise by 6.7% following a strong second quarter in 2026, reporting US$360.52 million in revenue and US$83.5 million in net income. The company also raised its full-year 2026 revenue outlook to between US$1.18 billion and US$1.28 billion and …

Is PTC Therapeutics (PTCT) Undervalued As Profit And Revenue Guidance Jumped?

PTC Therapeutics reported a significant shift from a loss to a net income of US$83.5 million in Q2 2026 and raised its full-year revenue guidance to US$1.18b-US$1.28b. Despite a recent share price increase of 9.56% over the past week, the stock is considered 23% …

Don't Ignore The Insider Selling In PTC Therapeutics

This article highlights recent insider selling at PTC Therapeutics (NASDAQ: PTCT), specifically noting that insiders sold shares worth US$1.4 million over the last year, with no purchases. Despite this, the company's market capitalization has increased, suggesting the insider selling might be opportunistic rather than …

PTC Therapeutics, Inc. (PTCT) Stock Forecasts

PTC Therapeutics, Inc. (PTCT) has received a "HOLD" investment rating from Argus, with a target price lowered to $79.00 from a current price of $73.31. The report highlights medium subratings for industry, financial strength, and value, while management, safety, and growth subratings are low. …

Have PTC Therapeutics Insiders Been Selling Stock?

PTC Therapeutics' CEO & Director, Matthew Klein, recently sold a portion of his shares for US$706k, reducing his holding by 6.2%. While this sale and an earlier one were below the current market price, indicating a potential negative signal, insiders still maintain significant ownership …

Zacks Research Downgrades PTC Therapeutics (NASDAQ:PTCT) to Hold

Zacks Research has downgraded PTC Therapeutics (NASDAQ:PTCT) from a "Strong Buy" to a "Hold" rating, despite the company's recent strong financial performance. PTC Therapeutics exceeded expectations in its latest quarterly results with an EPS of $0.92 and revenue of $360.52 million, a 101.5% year-over-year …

PTC Therapeutics CEO Klein sells $705,722 in company stock

Matthew B. Klein, CEO of PTC Therapeutics, sold 10,292 shares of company stock for $705,722 to cover tax withholding obligations related to RSU vesting. Following the sale, Klein beneficially owns 383,868 shares. Analysts predict the company will be profitable in 2026, with recent Q2 …

PTC Therapeutics (PTCT) CEO sells 10,292 shares to cover taxes

PTC Therapeutics CEO Matthew B. Klein sold 10,292 shares of common stock on August 4, 2026, at $68.57 per share to cover tax withholding obligations. This automatic "sell-to-cover" transaction was executed under a Rule 10b5-1 trading plan and was tied to the vesting of …

PTC Therapeutics, Inc. $PTCT Stock Position Lifted by California State Teachers Retirement System

California State Teachers Retirement System increased its stake in PTC Therapeutics (NASDAQ:PTCT) by 23.5% in the first quarter, now owning 84,320 shares. Several other major institutions, including Vanguard, Janus Henderson, and State Street, also expanded their positions in the biopharmaceutical company. Despite some insider …

PTC Therapeutics (PTCT) Stock Fair Value Edges Higher After Analyst Target Increases

Analyst price targets for PTC Therapeutics (PTCT) are increasing, with several firms raising their targets due to strong Sephience performance and a promising broader pipeline. This has led to a slight increase in the fair value estimate for PTCT, although some analysts maintain a …

PTCT Therapeutics (PTCT) insider to sell 10,292 vested shares under Rule 144

Matthew Klein, an insider at PTCT Therapeutics, has filed to sell 10,292 shares of common stock under Rule 144, valued at $705,754.35. These shares, which vested on August 3, 2026, were granted as compensation and are planned for sale on or after August 4, …

Top 3 Health Care Stocks You'll Regret Missing This Quarter

This article identifies three oversold healthcare stocks: Legend Biotech (LEGN), PTC Therapeutics (PTCT), and Indivior Pharmaceuticals (INDV), which recently announced a merger with Supernus Pharmaceuticals. These companies are highlighted due to their Relative Strength Index (RSI) being below 30, indicating they may be undervalued. …

PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PTC Therapeutics (PTCT) has seen a 20.3% loss in stock value over the past four weeks, but indicators suggest a potential trend reversal. The stock is currently in oversold territory with an RSI reading of 27.14, and Wall Street analysts have significantly raised their …

Empowered Funds LLC Sells 192,506 Shares of PTC Therapeutics, Inc. $PTCT

Empowered Funds LLC significantly reduced its stake in PTC Therapeutics, Inc. by selling 192,506 shares, retaining 57,906 shares valued at $3.95 million. This divestment occurred despite other major institutions increasing their holdings and PTC Therapeutics reporting strong quarterly results with EPS of $0.92 and …

PTC Therapeutics (PTCT) Is Down 11.5% After Raising 2026 Outlook And Boosting Profitability - Has The Bull Case Changed?

PTC Therapeutics reported strong Q2 2026 revenue of US$360.52 million and net income of US$83.5 million, leading to an increased full-year 2026 revenue outlook of US$1.18 billion to US$1.28 billion. Despite this positive financial report, the company's shares experienced an 11.47% weekly decline, prompting …

Price to book forward of PTC Therapeutics, Inc. – BX:P91

This article provides a financial data point for PTC Therapeutics, Inc. (BX:P91), specifically its "Price to book forward." It indicates the value and change for this metric over a specified period. The information is presented within the context of a trading and financial data …

PTC Therapeutics Inc (PTCT) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ...

PTC Therapeutics reported record quarterly revenue of $361 million for Q2 2026, driven by strong growth in Sephience revenue and other product sales, leading to a raised full-year product revenue guidance of $850 million to $950 million. The company highlighted positive interim data for …

PTC Therapeutics (PTCT) Stock Drops As Profit Surge Meets Launch Concentration Risk

PTC Therapeutics (PTCT) experienced a nearly 10% stock drop despite a strong Q2 2026 earnings report, which showed a significant revenue increase and a swing to profitability. The company's optimistic outlook relies on the success of Sephience and its pipeline, with Sephience showing strong …

PTC THERAPEUTICS, INC. : WELLS FARGO RAISES TARGET PRICE TO $106 FROM $93

Wells Fargo has increased its target price for PTC Therapeutics, Inc. from $93 to $106. This adjustment reflects an updated valuation for the company. The article, sourced from Reuters, includes a disclaimer noting that the content represents the author's opinion and should not be …

PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

PTC Therapeutics (PTCT) director details stock, options and RSUs

PTC Therapeutics director Hege Elisabeth Sollie-Zetlmayer has reported beneficial ownership of 46,526 shares of common stock, including multiple unvested RSU awards. She also holds several stock options, with three currently exercisable for a total of 65,125 shares at various exercise prices. Additional option grants …

Press Release: PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PTC Therapeutics announced its corporate update and second quarter 2026 financial results. The company provided an overview of its operational performance and key financial metrics for the quarter. This release offers insights into PTC Therapeutics' recent business developments and financial standing.

PTC Therapeutics: Q2 Earnings Snapshot

This article provides a Q2 earnings snapshot for PTC Therapeutics. The content, however, is minimal and appears to be a placeholder or an incomplete article, containing only privacy protection information and image links.

Earnings call transcript: PTC Therapeutics tops Q2 2026 forecasts on strong sales

PTC Therapeutics reported stronger-than-expected Q2 2026 results, with earnings of $0.92 per share and revenue of $361 million, significantly exceeding Wall Street forecasts. The company attributed its record revenue to strong Sephience sales and raised its full-year 2026 revenue guidance to $1.18 billion-$1.28 billion. …

PTC THERAPEUTICS ($PTCT) Releases Q2 2026 Earnings, Stock Rises

PTC Therapeutics (NASDAQ: PTCT) raises 2026 revenue guidance after strong Q2

PTC Therapeutics reported strong Q2 2026 results, achieving a net income of $83.5 million and total revenue of $361 million, significantly improving from a loss in Q2 2025. The company raised its full-year 2026 revenue guidance to $1.18 to $1.28 billion for total revenue …

PTC Therapeutics Inc (PTCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of PTC Therapeutics Inc (PTCT), highlighting its current price momentum, support, and resistance levels. It details various technical indicators like MACD, RSI, and Moving Averages, offering a comprehensive look at the stock's potential short-term movements. The analysis suggests …

PTC Therapeutics, Inc. (NASDAQ: PTCT) posts Q2 2026 profit, Phase 3 HD trial